Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
IDEAYA BiosciencesIDYA +0.40%53 Cash-to-Debt is 28.29 as of Jun. 2026, which is 39% below its 10-year median of 46.64. GuruFocus rates IDYA with a GF Score™ of 53/100 and a GF Value™ of $200.00 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 1,397 Biotechnology companies, IDEAYA Biosciences ranks better than 66.28% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. IDEAYA Biosciences's cash to debt ratio for the quarter that ended in Jun. 2026 was 28.29.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, IDEAYA Biosciencescould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for IDEAYA Biosciences's Cash-to-Debt or its related term are showing as below:
IDYA'
s Cash-to-Debt Range Over the Past 10 Years
Min: 10.21 Med: 46.64 Max: No Debt
Current: 28.29
During the past 9 years, IDEAYA Biosciences's highest Cash to Debt Ratio was No Debt. The lowest was 10.21. And the median was 46.64.
IDYA's Cash-to-Debt is ranked better than 66.28% of 1397
companies
in the Biotechnology industry
Industry Median: 6.78
vs IDYA: 28.29
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
IDEAYA Biosciences Cash-to-Debt Related Terms
IDEAYA Biosciences Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for IDEAYA Biosciences's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Biotechnology subindustry, IDEAYA Biosciences's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IDEAYA Biosciences Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, IDEAYA Biosciences's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where IDEAYA Biosciences's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IDEAYA Biosciences (IDYA) has a Cash-to-Debt of 28.29 as of Jun. 2026. This is 39% below median its historical median of 46.64. Over the past decade, IDEAYA Biosciences' Cash-to-Debt has ranged from 10.21 to 10,000.00. According to the industry distribution chart, IDEAYA Biosciences ranks #471 out of 1397 companies in the Biotechnology industry, placing it in the top 33.7%.
Is IDEAYA Biosciences' Cash-to-Debt too high?
IDEAYA Biosciences' current Cash-to-Debt of 28.29 is 39% below median its 10-year median of 46.64. Over the past 10 years, this metric has ranged from a low of 10.21 to a high of 10,000.00. The Biotechnology industry median Cash-to-Debt is 6.78. IDEAYA Biosciences' value of 28.29 is 317.3% above this industry median. Based on the distribution chart, IDEAYA Biosciences ranks #471 out of 1397 companies in the Biotechnology industry, which is above the industry midpoint. Overall, IDEAYA Biosciences has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does IDEAYA Biosciences' Cash-to-Debt compare to LEGN and DNLI?
According to the Biotechnology industry distribution chart, IDEAYA Biosciences ranks #471 out of 1397 companies for Cash-to-Debt. This puts IDEAYA Biosciences in the upper half of its industry. The industry median Cash-to-Debt is 6.78. IDEAYA Biosciences' value of 28.29 is 317.3% above this benchmark. Historically, IDEAYA Biosciences' own Cash-to-Debt has ranged from 10.21 to 10,000.00 over the past decade. While the company's 10-year median is 46.64 vs. the industry median of 6.78, IDEAYA Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 6.78, based on 1,397 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. IDEAYA Biosciences's current Cash-to-Debt of 28.29 is 317.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 6.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IDEAYA Biosciences's current Cash-to-Debt is 28.29, which is 39% below median its own 10-year median of 46.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IDEAYA Biosciences stock overvalued right now?
Based on GuruFocus' analysis, IDEAYA Biosciences (IDYA) is currently considered Possible Value Trap. The stock's GF Value™ is $200.00, compared to a current price of $37.59 — trading 81.2% below its estimated fair value. The current Cash-to-Debt is 28.29, which is 39% below median its 10-year median of 46.64 and 317.3% above the Biotechnology industry median of 6.78. IDEAYA Biosciences' overall GF Score™ is 53/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For IDEAYA Biosciences (IDYA), the current Cash-to-Debt is 28.29 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IDEAYA Biosciences (IDYA) Overvalued in 2026?
Based on GuruFocus' analysis, IDEAYA Biosciences stock appears to be undervalued.
The current stock price of $37.59 is trading 81.2% below its estimated GF Value™ of $200.00.
GuruFocus considers IDEAYA Biosciences to be Possible Value Trap.
Key valuation signals for IDYA:
Cash-to-Debt: 28.29 (39% below median its 10-year median of 46.64)
GF Value™: $200.00 vs. price of $37.59 (81.2% below fair value)
Industry Position: 317.3% above the Biotechnology median (#471 of 1397)
No single metric tells the full story. See the IDYA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
53GF Score
Get the complete analysis for IDYA
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IDYA has been successfully added to your 
